2, 3-Dichloro-4-methoxyphenyl 2-furyl ketone (E)-0 [2-(diethylamino) ethyl] oxime (ANP 4364) の健康人における臨床薬理学的検討

DOI

書誌事項

タイトル別名
  • Clinical pharmacology of 2, 3-dichloro-4-methoxyphenyl 2-furyl ketone (E)-0- [2-(diethylamino) ethyl] oxime (ANP 4364) in healthy volunteers

この論文をさがす

説明

A newly synthesized ketone oxime derivertive, 2, 3-dichloro-4-methoxyphenyl 2-furyl ketone (E)-0- [2-(diethylamino) ethyl] oxime (ANP 4364), was administered orally to 6 healthy volunteers to investigate its safety, pharmacodynamics, and pharmacokinetics.<BR>Six volunteers received single oral doses of 50, 100, 200 mg, and 3 consecutive doses of 100 mg, of ANP 4364.<BR>ANP 4364 caused slight hypotension, with a transient tachycardia, and a tendency towards increasing stroke volume revealed by impedance cardiography.<BR>No findings attributable to the drug were observed in the ECG or body temperature records.<BR>Pharmacokinetic analysis revealed that unchanged ANP 4364 was rapidly absorbed with a mean half-life of about 10 hours. After administration of 100 mg, 0.16% of the dose of ANP 4364 was excreted in urine within 24 hours. Subjective symptoms possibly produced by the drug were headache, a heavy feeling of the head, a feeling of warmth in the face, and numbness of the tongue ; there was one subject, however, who complained of nausea.<BR>Examination of the blood and urine showed no abnormal findings attributable to administration of the drug.<BR>In conclusion, it was found that ANP 4364 seems to have vasodilating action and is well-tolerated in man.

収録刊行物

  • 臨床薬理

    臨床薬理 10 (4), 495-507, 1979

    一般社団法人 日本臨床薬理学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ